Taken together, direct targeting of NOX4 has shown promises in attenuating oxidative stress, inflammation, fibrosis and dysfunction across preclinical models of heart failure, myocardial infarction, I/R injury, AF and diabetic cardiomyopathy (Table 4). Here, NOX4 is linked to atrial fibrillation.